GoodRx to Match Novo Nordisk Price for Oral Semaglutide
GoodRx announced oral semaglutide availability via its telemedicine platform at $149 for lower doses, matching Novo Nordisk pricing and intensifying the GLP-1 price war.
#pricing
7 stories
FDA Approves Eli Lilly Oral GLP-1 Foundayo — Rivalry With Oral Wegovy Begins
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
NBC News: FDA Approves GLP-1 Weight Loss Pill Foundayo with Six Dose Tiers
NBC News covers Foundayo's approval with self-pay pricing from $149-$349/month across six dose tiers. Medicare coverage for some patients could begin as early as summer 2026 with copays as low as $50/month.
Novo Nordisk Slashes Ozempic and Wegovy Prices Up to 48% in India
Novo Nordisk cut Ozempic prices 36% and Wegovy 48% in India as generic semaglutide from Dr Reddy's, Sun Pharma, and Zydus entered the market with prices as low as Rs 1,290/month.
New Self-Pay Pricing and Access Options for Tirzepatide
Pharmacist guide on new self-pay pricing for tirzepatide, navigating insurance and medication switching, with warnings against unsafe compounded GLP-1 products.
Eli Lilly and Novo Nordisk Strike MFN Deals to Lower GLP-1 Prices
Both pharma giants reached most-favored-nation pricing agreements with the Trump Administration to reduce costs of tirzepatide and semaglutide for American consumers.
Novo Nordisk to Slash US List Prices ~50% for Wegovy, Ozempic, and Rybelsus in 2027
Novo will reduce prices to $675/month starting January 1, 2027 — approximately 50% cut for Wegovy and 35% for Ozempic, aimed at patients on high-deductible plans.